Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01257750 · ClinicalTrials.gov registry record · Phase 1
Treatment of Corneal Neovascularization With Topical Pazopanib
A Phase 1 study, sponsored by Reza Dana, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01257750 is a Phase 1 study that has completed, run by Reza Dana, MD. The registered enrollment target is 20 participants.
The verdict
NCT01257750, a Phase 1 study, has completed, sponsored by Reza Dana, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of a drug \[Pazopanib (Votrient)\] as a treatment for corneal neovascularization. The cornea is the clear, central portion of the eye and neovascularization means blood vessel growth. The cornea is typically avascular, or without blood vessels. Corneal neovascularization in the cornea and can put vision at risk. Numerous diseases of the cornea such as inflammation, ischemia (restriction of blood supply), infection, degeneration (or deterioration), trauma, or corneal stem cell deficiency can lead to corneal neovascularization. This major ocular complication can lead to corneal scarring, edema (swelling), lipid deposits, and inflammation that may significantly alter your vision. In addition, it worsens the outcome of potential future treatments, such as a corneal transplant. A corneal transplant is a treatment that many patients with severe corneal disease may ultimately need.
Interventions
- DRUG Pazopanib (5mg/ml)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01257750
The ClinicalTrials.gov registry entry for NCT01257750 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reza Dana, MD, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pazopanib (5mg/ml) is the first listed.
NCT01257750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01257750 about?
NCT01257750 is a clinical study titled "Treatment of Corneal Neovascularization With Topical Pazopanib". The purpose of this study is to determine the safety and efficacy of a drug \[Pazopanib (Votrient)\] as a treatment for corneal neovascularization. The cornea is the clear, central portion of the eye and neovascularization means blood vessel growth. The cornea is typically avascular, or without bloo...
What is the current status of trial NCT01257750?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01257750?
The interventions under investigation include: Pazopanib (5mg/ml) (DRUG).
Who is sponsoring clinical trial NCT01257750?
This trial is sponsored by Reza Dana, MD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.